Literature DB >> 29064022

Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.

Naveen Pemmaraju1.   

Abstract

Entities:  

Keywords:  BCL2; BPDCN; Bromodomain; IL3R, CD123; NFkB; Targeted therapy

Mesh：

Substances：

Year:  2017        PMID： 29064022     DOI： 10.1007/s11899-017-0425-7

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


× No keyword cloud information.
  27 in total

1.  Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin.

Authors:  L Brunetti; V Di Battista; A Venanzi; G Schiavoni; M P Martelli; S Ascani; C Mecucci; E Tiacci; B Falini
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

2.  Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.

Authors:  Joan Montero; Jason Stephansky; Tianyu Cai; Gabriel K Griffin; Lucia Cabal-Hierro; Katsuhiro Togami; Leah J Hogdal; Ilene Galinsky; Elizabeth A Morgan; Jon C Aster; Matthew S Davids; Nicole R LeBoeuf; Richard M Stone; Marina Konopleva; Naveen Pemmaraju; Anthony Letai; Andrew A Lane
Journal:  Cancer Discov       Date:  2016-12-16       Impact factor: 39.397

3.  CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.

Authors:  Challice L Bonifant; Arpad Szoor; David Torres; Nicholos Joseph; Mireya Paulina Velasquez; Kota Iwahori; Amos Gaikwad; Phuong Nguyen; Caroline Arber; Xiao-Tong Song; Michele Redell; Stephen Gottschalk
Journal:  Mol Ther       Date:  2016-06-06       Impact factor: 11.454

4.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

5.  Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

Authors:  Eva Nievergall; Hayley S Ramshaw; Agnes S M Yong; Mark Biondo; Samantha J Busfield; Gino Vairo; Angel F Lopez; Timothy P Hughes; Deborah L White; Devendra K Hiwase
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

6.  Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.

Authors:  Anouk Emadali; Neda Hoghoughi; Samuel Duley; Azadeh Hajmirza; Els Verhoeyen; Francois-Loic Cosset; Philippe Bertrand; Christophe Roumier; Anne Roggy; Céline Suchaud-Martin; Martine Chauvet; Sarah Bertrand; Sieme Hamaidia; Sophie Rousseaux; Véronique Josserand; Julie Charles; Isabelle Templier; Takahiro Maeda; Juliana Bruder-Costa; Laurence Chaperot; Joel Plumas; Marie-Christine Jacob; Thierry Bonnefoix; Sophie Park; Remy Gressin; Cornelis P Tensen; Cristina Mecucci; Elizabeth Macintyre; Dominique Leroux; Elisabeth Brambilla; Florence Nguyen-Khac; Isabelle Luquet; Dominique Penther; Christian Bastard; Fabrice Jardin; Christine Lefebvre; Francine Garnache; Mary B Callanan
Journal:  Blood       Date:  2016-04-08       Impact factor: 22.113

Review 7.  Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation.

Authors:  Mohamed A Kharfan-Dabaja; Hillard M Lazarus; Taiga Nishihori; Rami A Mahfouz; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-05       Impact factor: 5.742

Review 8.  Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.

Authors:  Livio Pagano; Caterina G Valentini; Sara Grammatico; Alessandro Pulsoni
Journal:  Br J Haematol       Date:  2016-06-05       Impact factor: 6.998

9.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

10.  Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.

Authors:  Laure Philippe; Adam Ceroi; Elodie Bôle-Richard; Alizée Jenvrin; Sabeha Biichle; Sophie Perrin; Samuel Limat; Francis Bonnefoy; Eric Deconinck; Philippe Saas; Francine Garnache-Ottou; Fanny Angelot-Delettre
Journal:  Haematologica       Date:  2017-08-10       Impact factor: 9.941
View more
  9 in total

Review 1.  Recent Updates on Chronic Myelomonocytic Leukemia.

Authors:  Sanam Loghavi; Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

2.  How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Authors:  Francine Garnache-Ottou; Chrystelle Vidal; Sabeha Biichlé; Florian Renosi; Eve Poret; Maïder Pagadoy; Maxime Desmarets; Anne Roggy; Estelle Seilles; Lou Soret; Françoise Schillinger; Sandrine Puyraimond; Tony Petrella; Claude Preudhomme; Christophe Roumier; Elisabeth A MacIntyre; Véronique Harrivel; Yohan Desbrosses; Bérengère Gruson; Franck Geneviève; Sylvain Thepot; Yuriy Drebit; Thibaut Leguay; François-Xavier Gros; Nicolas Lechevalier; Pascale Saussoy; Véronique Salaun; Edouard Cornet; Zehaira Benseddik; Richard Veyrat-Masson; Orianne Wagner-Ballon; Célia Salanoubat; Marc Maynadié; Julien Guy; Denis Caillot; Marie-Christine Jacob; Jean-Yves Cahn; Rémy Gressin; Johann Rose; Bruno Quesnel; Estelle Guerin; Franck Trimoreau; Jean Feuillard; Marie-Pierre Gourin; Adriana Plesa; Lucile Baseggio; Isabelle Arnoux; Norbert Vey; Didier Blaise; Romaric Lacroix; Christine Arnoulet; Blandine Benet; Véronique Dorvaux; Caroline Bret; Bernard Drenou; Agathe Debliquis; Véronique Latger-Cannard; Caroline Bonmati; Marie-Christine Bene; Pierre Peterlin; Michel Ticchioni; Pierre-Simon Rohrlich; Anne Arnaud; Stefan Wickenhauser; Valérie Bardet; Sabine Brechignac; Benjamin Papoular; Victoria Raggueneau; Jacques Vargaftig; Rémi Letestu; Daniel Lusina; Thorsten Braun; Vincent Foissaud; Jérôme Tamburini; Hind Bennani; Nicolas Freynet; Catherine Cordonnier; Magali Le Garff-Tavernier; Nathalie Jacques; Karim Maloum; Damien Roos-Weil; Didier Bouscary; Vahid Asnafi; Ludovic Lhermitte; Felipe Suarez; Etienne Lengline; Frédéric Féger; Giorgia Battipaglia; Mohamad Mohty; Sabrina Bouyer; Ouda Ghoual; Elodie Dindinaud; Caroline Basle; Mathieu Puyade; Carinne Lafon; Thierry Fest; Mikael Roussel; Xavier Cahu; Elsa Bera; Sylvie Daliphard; Fabrice Jardin; Lydia Campos; Françoise Solly; Denis Guyotat; Anne-Cécile Galoisy; Alice Eischen; Caroline Mayeur-Rousse; Blandine Guffroy; Christian Recher; Marie Loosveld; Alice Garnier; Vincent Barlogis; Maria Alessandra Rosenthal; Sophie Brun; Nathalie Contentin; Sébastien Maury; Mary Callanan; Christine Lefebvre; Natacha Maillard; Patricia Okamba; Christophe Ferrand; Olivier Adotevi; Philippe Saas; Fanny Angelot-Delettre; Delphine Binda; Eric Deconinck
Journal:  Blood Adv       Date:  2019-12-23

3.  Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.

Authors:  Justin Taylor; Michael Haddadin; Vivek A Upadhyay; Erwin Grussie; Neha Mehta-Shah; Andrew M Brunner; Abner Louissaint; Scott B Lovitch; Ahmet Dogan; Amir T Fathi; Richard M Stone; Martin S Tallman; Raajit K Rampal; Donna S Neuberg; Kristen E Stevenson; Steven M Horwitz; Andrew A Lane
Journal:  Blood       Date:  2019-06-26       Impact factor: 22.113

Review 4.  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community.

Authors:  Naveen Pemmaraju; Audun Utengen; Vikas Gupta; Michael A Thompson; Andrew A Lane
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 5.  Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.

Authors:  Guillaume Beziat; Loïc Ysebaert
Journal:  Onco Targets Ther       Date:  2020-06-09       Impact factor: 4.147

6.  Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.

Authors:  Tianyu Cai; Agnès Gouble; Kathryn L Black; Anna Skwarska; Ammar S Naqvi; Deanne Taylor; Ming Zhao; Qi Yuan; Mayumi Sugita; Qi Zhang; Roman Galetto; Stéphanie Filipe; Antonio Cavazos; Lina Han; Vinitha Kuruvilla; Helen Ma; Connie Weng; Chang-Gong Liu; Xiuping Liu; Sergej Konoplev; Jun Gu; Guilin Tang; Xiaoping Su; Gheath Al-Atrash; Stefan Ciurea; Sattva S Neelapu; Andrew A Lane; Hagop Kantarjian; Monica L Guzman; Naveen Pemmaraju; Julianne Smith; Andrei Thomas-Tikhonenko; Marina Konopleva
Journal:  Nat Commun       Date:  2022-04-28       Impact factor: 17.694

Review 7.  CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review.

Authors:  Ler Yie Chan; Sylvia Annabel Dass; Gee Jun Tye; Siti A M Imran; Wan Safwani Wan Kamarul Zaman; Fazlina Nordin
Journal:  Biomedicines       Date:  2022-03-30

8.  Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.

Authors:  Naveen Pemmaraju; Marina Konopleva
Journal:  Blood Adv       Date:  2020-08-25

9.  First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.

Authors:  Weili Sun; Huaying Liu; Young Kim; Nicole Karras; Anna Pawlowska; Debbie Toomey; Wade Kyono; Paul Gaynon; Joseph Rosenthal; Anthony Stein
Journal:  J Hematol Oncol       Date:  2018-05-02       Impact factor: 17.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.